Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2022-04-28 / J Cancer Res Clin Oncol 2023 Apr;149(4):1425-1441Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2022-03-10 / Ther Apher Dial 2022 Jun;26(3):537-547A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-03-08 / Expert Rev Vaccines 2022 Apr;21(4):513-531Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma
/in Dendritic Cells, International Publications, Malignant Lymphoma /von 2022-02-15 / Leuk Lymphoma 2022 Jul;63(7):1733-1737Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-02-04 / Curr Oncol 2022 Feb;29(2):881-891Research progress on dendritic cell vaccines in cancer immunotherapy
/in Dendritic Cells, International Publications /von 2022-01-24 / Exp Hematol Oncol 2022 Jan;11(1):3Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications, Newcastle Disease Virus /von 2022-01-19 / Genes Immun 2022 02;23(1):1-11GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2022-01-07 / J Healthc Eng 2022;2022:2518847
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de